Ezetimibe
Abdominal Obesity-Metabolic Syndrome
Explore 42 assets in Abdominal Obesity-Metabolic Syndrome →Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Samsung Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07219602CT.gov A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | — | Recruiting | — | — | — |
NCT05845424CT.gov High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium | — | Recruiting | — | — | — |
NCT01849068CT.gov Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study | — | Completed | — | — | — |
NCT00817843CT.gov The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study | — | Completed | — | — | — |
NCT00819403CT.gov Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment | — | Completed | — | — | — |
NCT00485121CT.gov Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis | — | Completed | — | — | — |
NCT00988364CT.gov Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. | — | Completed | — | — | — |
NCT00409773CT.gov Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED) | — | Completed | — | — | — |
NCT00189085CT.gov Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Abdominal Obesity-Metabolic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ezetimibe (this asset) | Samsung Medical Center | Approved | BB · 71 |
| Topiramate | All India Institute of Medical Sciences, Bhubaneswar | P4 | BBB |
| Atorvastatin | Seoul National University Hospital | P4 | BBB |
| Pioglitazone | Philip Kern | P4 | BBB |
| Simvastatin | Jaime Daniel Mondragon | P4 | BBB |
| Olmesartan Medoxomil | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | P4 | BBB |
| Rosuvastatin | Hamdard University | P4 | BBB |
| Amlodipine | Italo Biaggioni | P4 | BB |
| Telmisartan | Hamdard University | P4 | BB |
+42 more in the Abdominal Obesity-Metabolic Syndrome cohort
Other indications for Ezetimibe
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Coronary Artery Disorder | — | P4 | BBB · 76 |
| Inherited Lipid Metabolism Disorder | — | P4 | BBB · 75 |
| Hyperlipidemia | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ezetimibe in Abdominal Obesity-Metabolic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ezetimibe-abdominal-obesity-metabolic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →